<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04742010</url>
  </required_header>
  <id_info>
    <org_study_id>20/41068</org_study_id>
    <nct_id>NCT04742010</nct_id>
  </id_info>
  <brief_title>Zoledronic Acid for Prevention of Bone Loss After BAriatric Surgery (ZABAS)</brief_title>
  <acronym>ZABAS</acronym>
  <official_title>Zoledronic Acid for Prevention of Bone Loss After BAriatric Surgery (ZABAS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stinus Gadegaard Hansen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Research Unit of Health Sciences, Hospital of South West Jutland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Regional Health Research, University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>OPEN - Odense Patient data Explorative Network, The University of Southern Denmark, Odense, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Radiology and Nuclear Medicine, Hospital of Southwest Jutland, 6700 Esbjerg, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital of South West Jutland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a randomised placebo-controlled trial assess effects of zoledronic acid for prevention of&#xD;
      bone and muscle loss after bariatric surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In individuals with severe obesity, bariatric surgery effectively reduces body weight,&#xD;
      improves obesity related diseases and lowers mortality. A loss of bone and muscle mass and an&#xD;
      increase in bone fracture risk are however seen after surgery. In this study it is examined&#xD;
      if treatment with zoledronic acid (a drug used to treat osteoporosis) can prevent the bone&#xD;
      and muscle loss after bariatric surgery. A single infusion of zoledronic acid or placebo is&#xD;
      given before surgery. The study is blinded and randomized for methodological reasons. Bone&#xD;
      and muscle scans, tests of muscle strength and physical performance and blood samples (for&#xD;
      analysis of markers related to bone and muscle metabolism) are performed at inclusion and 12&#xD;
      and 24 months after surgery. A total of 50 adult individuals will participate. Results will&#xD;
      be important for the evidence-based care of patients undergoing bariatric surgery and&#xD;
      zoledronic acid.&#xD;
&#xD;
      Study design This is a single center randomized double-blind placebo-controlled study of&#xD;
      zoledronic acid for prevention of bone and muscle loss after bariatric surgery. Routine&#xD;
      bariatric surgery (RYGB or gastric sleeve) will be performed. The end of study is 24 months&#xD;
      after surgery.&#xD;
&#xD;
      Study Population Patients referred for bariatric surgery at The Hospital South West Jutland,&#xD;
      Esbjerg will be invited to participate.&#xD;
&#xD;
      Randomization After inclusion and baseline assessment, patients will be randomly assigned to&#xD;
      either zoledronic acid or placebo with a 1:1 allocation. A randomization code stratifying an&#xD;
      equal number of participants having RYGB or SG into each study arm will be applied.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitative Computed Tomography (QCT)</measure>
    <time_frame>Change from baseline to 12 and 24 months after bariatric surgery</time_frame>
    <description>Volumetric bone mineral density at the lumbar spine (L1 -L2) (Mindways QCT Pro software, Texas, USA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QCT</measure>
    <time_frame>Change from baseline to 12 and 24 months after bariatric surgery</time_frame>
    <description>Volumetric BMD at the proximal femur (Mindways QCT Pro software, Texas, USA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical calcium-metabolic markers</measure>
    <time_frame>Change from baseline to 12 and 24 months after bariatric surgery</time_frame>
    <description>Calcium, parathyroid hormone, vitamin D and markers of bone remodeling (CTX, P1NP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DEXA</measure>
    <time_frame>Change from baseline to 12 and 24 months after bariatric surgery</time_frame>
    <description>Bone mineral density at the lumbar spine and total hip (Hologic Discovery, Waltham, MA, US).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HR-pQCT</measure>
    <time_frame>Change from baseline to 12 and 24 months after bariatric surgery</time_frame>
    <description>Radius and tibia bone microarchitecture (Scanco Medical AG, Brutisellen, Switzerland).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical bone stiffness</measure>
    <time_frame>Change from baseline to 12 and 24 months after bariatric surgery</time_frame>
    <description>Cortical bone material strength index (BMSi) assessed using microindentation at the anterior surface of the mid-tibia diaphysis (OsteoProbe, Active Life Scientific, California, US).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Strength</measure>
    <time_frame>Change from baseline to 12 and 24 months after bariatric surgery</time_frame>
    <description>Upper and lower limb muscle strength assessed using dynamometers (foot, knee, shoulder, hand)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical function</measure>
    <time_frame>Change from baseline to 12 and 24 months after bariatric surgery</time_frame>
    <description>Short physical performance battery (SPPB), Stair Climb, 2 minute walking test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Bone Loss</condition>
  <condition>Muscle Atrophy</condition>
  <condition>Bariatric Surgery</condition>
  <arm_group>
    <arm_group_label>Zoledronic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic Acid</intervention_name>
    <description>A single treatment 21 days before bariatric surgery with Zoledronic acid 5 mg or placebo&#xD;
Pharmaceutical form: Solution for infusion (100 ml normal saline containing 5 mg zoledronic acid or placebo)&#xD;
Administration: slow intravenous infusion with a duration of at least 15 minutes</description>
    <arm_group_label>Zoledronic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>as above</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  35 years old or older&#xD;
&#xD;
          -  Eligible for bariatric surgery (BMI&gt;35 kg/m2 with obesity-related comorbidity)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Chronic kidney disease with estimated GFR&lt;45 ml/min.&#xD;
&#xD;
          -  Hypocalcemia .&#xD;
&#xD;
          -  Hypersensitivity to bisphosphonates, mannitol, sodium citrate or water.&#xD;
&#xD;
          -  Metabolic bone disease (osteoporosis is allowed).&#xD;
&#xD;
          -  Prior treatment with anti-osteoporotic agents.&#xD;
&#xD;
          -  Treatment with oral glucocorticoids&#xD;
&#xD;
          -  Other diseases with known effects on bone metabolism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stinus Gadegaard Hansen, MD, PhD</last_name>
    <phone>+45 27594121</phone>
    <email>Stinus.Gadegaard.Hansen@rsyd.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital South West Jutland</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stinus Gadegaard Hansen, Medical Doctor</last_name>
      <email>Stinus.Gadegaard.Hansen@rsyd.dk</email>
    </contact>
    <contact_backup>
      <last_name>Søren Gam, Master of Sports Science</last_name>
      <email>soren.gam@rsyd.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, Mullany EC, Biryukov S, Abbafati C, Abera SF, Abraham JP, Abu-Rmeileh NM, Achoki T, AlBuhairan FS, Alemu ZA, Alfonso R, Ali MK, Ali R, Guzman NA, Ammar W, Anwari P, Banerjee A, Barquera S, Basu S, Bennett DA, Bhutta Z, Blore J, Cabral N, Nonato IC, Chang JC, Chowdhury R, Courville KJ, Criqui MH, Cundiff DK, Dabhadkar KC, Dandona L, Davis A, Dayama A, Dharmaratne SD, Ding EL, Durrani AM, Esteghamati A, Farzadfar F, Fay DF, Feigin VL, Flaxman A, Forouzanfar MH, Goto A, Green MA, Gupta R, Hafezi-Nejad N, Hankey GJ, Harewood HC, Havmoeller R, Hay S, Hernandez L, Husseini A, Idrisov BT, Ikeda N, Islami F, Jahangir E, Jassal SK, Jee SH, Jeffreys M, Jonas JB, Kabagambe EK, Khalifa SE, Kengne AP, Khader YS, Khang YH, Kim D, Kimokoti RW, Kinge JM, Kokubo Y, Kosen S, Kwan G, Lai T, Leinsalu M, Li Y, Liang X, Liu S, Logroscino G, Lotufo PA, Lu Y, Ma J, Mainoo NK, Mensah GA, Merriman TR, Mokdad AH, Moschandreas J, Naghavi M, Naheed A, Nand D, Narayan KM, Nelson EL, Neuhouser ML, Nisar MI, Ohkubo T, Oti SO, Pedroza A, Prabhakaran D, Roy N, Sampson U, Seo H, Sepanlou SG, Shibuya K, Shiri R, Shiue I, Singh GM, Singh JA, Skirbekk V, Stapelberg NJ, Sturua L, Sykes BL, Tobias M, Tran BX, Trasande L, Toyoshima H, van de Vijver S, Vasankari TJ, Veerman JL, Velasquez-Melendez G, Vlassov VV, Vollset SE, Vos T, Wang C, Wang X, Weiderpass E, Werdecker A, Wright JL, Yang YC, Yatsuya H, Yoon J, Yoon SJ, Zhao Y, Zhou M, Zhu S, Lopez AD, Murray CJ, Gakidou E. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014 Aug 30;384(9945):766-81. doi: 10.1016/S0140-6736(14)60460-8. Epub 2014 May 29. Erratum in: Lancet. 2014 Aug 30;384(9945):746.</citation>
    <PMID>24880830</PMID>
  </reference>
  <reference>
    <citation>Arterburn D, Gupta A. Comparing the Outcomes of Sleeve Gastrectomy and Roux-en-Y Gastric Bypass for Severe Obesity. JAMA. 2018 Jan 16;319(3):235-237. doi: 10.1001/jama.2017.20449.</citation>
    <PMID>29340659</PMID>
  </reference>
  <reference>
    <citation>Yu EW. Bone metabolism after bariatric surgery. J Bone Miner Res. 2014 Jul;29(7):1507-18. doi: 10.1002/jbmr.2226. Review. Erratum in: J Bone Miner Res. 2018 May;33(5):959.</citation>
    <PMID>24677277</PMID>
  </reference>
  <reference>
    <citation>Rousseau C, Jean S, Gamache P, Lebel S, Mac-Way F, Biertho L, Michou L, Gagnon C. Change in fracture risk and fracture pattern after bariatric surgery: nested case-control study. BMJ. 2016 Jul 27;354:i3794. doi: 10.1136/bmj.i3794.</citation>
    <PMID>27814663</PMID>
  </reference>
  <reference>
    <citation>Yu EW, Lee MP, Landon JE, Lindeman KG, Kim SC. Fracture Risk After Bariatric Surgery: Roux-en-Y Gastric Bypass Versus Adjustable Gastric Banding. J Bone Miner Res. 2017 Jun;32(6):1229-1236. doi: 10.1002/jbmr.3101. Epub 2017 Mar 20.</citation>
    <PMID>28251687</PMID>
  </reference>
  <reference>
    <citation>Lalmohamed A, de Vries F, Bazelier MT, Cooper A, van Staa TP, Cooper C, Harvey NC. Risk of fracture after bariatric surgery in the United Kingdom: population based, retrospective cohort study. BMJ. 2012 Aug 3;345:e5085. doi: 10.1136/bmj.e5085.</citation>
    <PMID>22867649</PMID>
  </reference>
  <reference>
    <citation>Lu CW, Chang YK, Chang HH, Kuo CS, Huang CT, Hsu CC, Huang KC. Fracture Risk After Bariatric Surgery: A 12-Year Nationwide Cohort Study. Medicine (Baltimore). 2015 Dec;94(48):e2087. doi: 10.1097/MD.0000000000002087.</citation>
    <PMID>26632892</PMID>
  </reference>
  <reference>
    <citation>Nakamura KM, Haglind EG, Clowes JA, Achenbach SJ, Atkinson EJ, Melton LJ 3rd, Kennel KA. Fracture risk following bariatric surgery: a population-based study. Osteoporos Int. 2014 Jan;25(1):151-8. doi: 10.1007/s00198-013-2463-x. Epub 2013 Aug 3.</citation>
    <PMID>23912559</PMID>
  </reference>
  <reference>
    <citation>Axelsson KF, Werling M, Eliasson B, Szabo E, Näslund I, Wedel H, Lundh D, Lorentzon M. Fracture Risk After Gastric Bypass Surgery: A Retrospective Cohort Study. J Bone Miner Res. 2018 Dec;33(12):2122-2131. doi: 10.1002/jbmr.3553. Epub 2018 Aug 13.</citation>
    <PMID>30011091</PMID>
  </reference>
  <reference>
    <citation>Frederiksen KD, Hanson S, Hansen S, Brixen K, Gram J, Jørgensen NR, Støving RK. Bone Structural Changes and Estimated Strength After Gastric Bypass Surgery Evaluated by HR-pQCT. Calcif Tissue Int. 2016 Mar;98(3):253-62. doi: 10.1007/s00223-015-0091-5. Epub 2015 Dec 12.</citation>
    <PMID>26661530</PMID>
  </reference>
  <reference>
    <citation>Andersen S, Frederiksen KD, Hansen S, Brixen K, Gram J, Støving RK. Bone structure and estimated bone strength in obese patients evaluated by high-resolution peripheral quantitative computed tomography. Calcif Tissue Int. 2014 Jul;95(1):19-28. doi: 10.1007/s00223-014-9857-4. Epub 2014 Apr 17.</citation>
    <PMID>24736885</PMID>
  </reference>
  <reference>
    <citation>Shanbhogue VV, Støving RK, Frederiksen KH, Hanson S, Brixen K, Gram J, Jørgensen NR, Hansen S. Bone structural changes after gastric bypass surgery evaluated by HR-pQCT: a two-year longitudinal study. Eur J Endocrinol. 2017 Jun;176(6):685-693. doi: 10.1530/EJE-17-0014. Epub 2017 Mar 13.</citation>
    <PMID>28289103</PMID>
  </reference>
  <reference>
    <citation>Lindeman KG, Greenblatt LB, Rourke C, Bouxsein ML, Finkelstein JS, Yu EW. Longitudinal 5-Year Evaluation of Bone Density and Microarchitecture After Roux-en-Y Gastric Bypass Surgery. J Clin Endocrinol Metab. 2018 Nov 1;103(11):4104-4112. doi: 10.1210/jc.2018-01496.</citation>
    <PMID>30219833</PMID>
  </reference>
  <reference>
    <citation>Muschitz C, Kocijan R, Marterer C, Nia AR, Muschitz GK, Resch H, Pietschmann P. Sclerostin levels and changes in bone metabolism after bariatric surgery. J Clin Endocrinol Metab. 2015 Mar;100(3):891-901. doi: 10.1210/jc.2014-3367. Epub 2014 Dec 9.</citation>
    <PMID>25490275</PMID>
  </reference>
  <reference>
    <citation>Gagnon C, Schafer AL. Bone Health After Bariatric Surgery. JBMR Plus. 2018 May 1;2(3):121-133. doi: 10.1002/jbm4.10048. eCollection 2018 May. Review.</citation>
    <PMID>30283897</PMID>
  </reference>
  <reference>
    <citation>Schafer AL, Weaver CM, Black DM, Wheeler AL, Chang H, Szefc GV, Stewart L, Rogers SJ, Carter JT, Posselt AM, Shoback DM, Sellmeyer DE. Intestinal Calcium Absorption Decreases Dramatically After Gastric Bypass Surgery Despite Optimization of Vitamin D Status. J Bone Miner Res. 2015 Aug;30(8):1377-85. doi: 10.1002/jbmr.2467. Epub 2015 May 21.</citation>
    <PMID>25640580</PMID>
  </reference>
  <reference>
    <citation>Yu EW, Wewalka M, Ding SA, Simonson DC, Foster K, Holst JJ, Vernon A, Goldfine AB, Halperin F. Effects of Gastric Bypass and Gastric Banding on Bone Remodeling in Obese Patients With Type 2 Diabetes. J Clin Endocrinol Metab. 2016 Feb;101(2):714-22. doi: 10.1210/jc.2015-3437. Epub 2015 Nov 24.</citation>
    <PMID>26600045</PMID>
  </reference>
  <reference>
    <citation>Muschitz C, Kocijan R, Haschka J, Zendeli A, Pirker T, Geiger C, Müller A, Tschinder B, Kocijan A, Marterer C, Nia A, Muschitz GK, Resch H, Pietschmann P. The Impact of Vitamin D, Calcium, Protein Supplementation, and Physical Exercise on Bone Metabolism After Bariatric Surgery: The BABS Study. J Bone Miner Res. 2016 Mar;31(3):672-82. doi: 10.1002/jbmr.2707. Epub 2015 Sep 30.</citation>
    <PMID>26350034</PMID>
  </reference>
  <reference>
    <citation>Mundbjerg LH, Stolberg CR, Bladbjerg EM, Funch-Jensen P, Juhl CB, Gram B. Effects of 6 months supervised physical training on muscle strength and aerobic capacity in patients undergoing Roux-en-Y gastric bypass surgery: a randomized controlled trial. Clin Obes. 2018 Aug;8(4):227-235. doi: 10.1111/cob.12256. Epub 2018 Jun 12.</citation>
    <PMID>29896844</PMID>
  </reference>
  <reference>
    <citation>Frost HM. Bone's mechanostat: a 2003 update. Anat Rec A Discov Mol Cell Evol Biol. 2003 Dec;275(2):1081-101. Review.</citation>
    <PMID>14613308</PMID>
  </reference>
  <reference>
    <citation>Tagliaferri C, Wittrant Y, Davicco MJ, Walrand S, Coxam V. Muscle and bone, two interconnected tissues. Ageing Res Rev. 2015 May;21:55-70. doi: 10.1016/j.arr.2015.03.002. Epub 2015 Mar 21. Review.</citation>
    <PMID>25804855</PMID>
  </reference>
  <reference>
    <citation>Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007 May 3;356(18):1809-22.</citation>
    <PMID>17476007</PMID>
  </reference>
  <reference>
    <citation>Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, Rizzoli R, Lipschitz S, Dimai HP, Witvrouw R, Eriksen E, Brixen K, Russo L, Claessens F, Papanastasiou P, Antunez O, Su G, Bucci-Rechtweg C, Hruska J, Incera E, Vanderschueren D, Orwoll E. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012 Nov 1;367(18):1714-23. doi: 10.1056/NEJMoa1204061.</citation>
    <PMID>23113482</PMID>
  </reference>
  <reference>
    <citation>Deas CM, Murphy P, Iranikhah M, Freeman MK. Retained Skeletal Effects of Zoledronic Acid Following Discontinuation of Treatment: A Review of the Literature. Consult Pharm. 2017 Mar 1;32(3):144-155. doi: 10.4140/TCP.n.2017.144. Review.</citation>
    <PMID>28270269</PMID>
  </reference>
  <reference>
    <citation>Watanabe R, Fujita N, Takeda S, Sato Y, Kobayashi T, Morita M, Oike T, Miyamoto K, Matsumoto Y, Matsumoto M, Nakamura M, Miyamoto T. Ibandronate concomitantly blocks immobilization-induced bone and muscle atrophy. Biochem Biophys Res Commun. 2016 Nov 25;480(4):662-668. doi: 10.1016/j.bbrc.2016.10.112. Epub 2016 Oct 27.</citation>
    <PMID>27983979</PMID>
  </reference>
  <reference>
    <citation>Børsheim E, Herndon DN, Hawkins HK, Suman OE, Cotter M, Klein GL. Pamidronate attenuates muscle loss after pediatric burn injury. J Bone Miner Res. 2014 Jun;29(6):1369-72. doi: 10.1002/jbmr.2162.</citation>
    <PMID>24347438</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 27, 2021</study_first_submitted>
  <study_first_submitted_qc>February 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital of South West Jutland</investigator_affiliation>
    <investigator_full_name>Stinus Gadegaard Hansen</investigator_full_name>
    <investigator_title>Endocrinologist, Associate professor, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

